Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer.


Journal

NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891

Informations de publication

Date de publication:
17 May 2023
Historique:
received: 24 10 2022
accepted: 28 04 2023
medline: 18 5 2023
pubmed: 18 5 2023
entrez: 17 5 2023
Statut: epublish

Résumé

Prognostic markers currently utilized in clinical practice for estrogen receptor-positive (ER+) and lymph node-negative (LN-) invasive breast cancer (IBC) patients include the Nottingham grading system and Oncotype Dx (ODx). However, these biomarkers are not always optimal and remain subject to inter-/intra-observer variability and high cost. In this study, we evaluated the association between computationally derived image features from H&E images and disease-free survival (DFS) in ER+ and LN- IBC. H&E images from a total of n = 321 patients with ER+ and LN- IBC from three cohorts were employed for this study (Training set: D1 (n = 116), Validation sets: D2 (n = 121) and D3 (n = 84)). A total of 343 features relating to nuclear morphology, mitotic activity, and tubule formation were computationally extracted from each slide image. A Cox regression model (IbRiS) was trained to identify significant predictors of DFS and predict a high/low-risk category using D1 and was validated on independent testing sets D2 and D3 as well as within each ODx risk category. IbRiS was significantly prognostic of DFS with a hazard ratio (HR) of 2.33 (95% confidence interval (95% CI) = 1.02-5.32, p = 0.045) on D2 and a HR of 2.94 (95% CI = 1.18-7.35, p = 0.0208) on D3. In addition, IbRiS yielded significant risk stratification within high ODx risk categories (D1 + D2: HR = 10.35, 95% CI = 1.20-89.18, p = 0.0106; D1: p = 0.0238; D2: p = 0.0389), potentially providing more granular risk stratification than offered by ODx alone.

Identifiants

pubmed: 37198173
doi: 10.1038/s41523-023-00545-y
pii: 10.1038/s41523-023-00545-y
pmc: PMC10192429
doi:

Types de publication

Journal Article

Langues

eng

Pagination

40

Subventions

Organisme : NCI NIH HHS
ID : R01 CA216579
Pays : United States
Organisme : NCRR NIH HHS
ID : C06 RR012463
Pays : United States
Organisme : NIBIB NIH HHS
ID : R43 EB028736
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA239055
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA249992
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA220581
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA202752
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA208236
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA248226
Pays : United States
Organisme : BLRD VA
ID : I01 BX004121
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA257612
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA254566
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Breast. 2020 Feb;49:267-273
pubmed: 31935669
Lab Invest. 2018 Nov;98(11):1438-1448
pubmed: 29959421
Pathol Res Pract. 1990 Dec;186(6):732-6
pubmed: 1964730
Cancer. 1994 Jul 1;74(1 Suppl):381-400
pubmed: 8004612
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
Nat Rev Clin Oncol. 2019 Nov;16(11):703-715
pubmed: 31399699
Breast Cancer Res Treat. 2012 Jun;133(2):553-61
pubmed: 21964579
Acta Oncol. 2000;39(1):41-5
pubmed: 10752652
J Surg Oncol. 1999 Jun;71(2):101-5
pubmed: 10389866
N Engl J Med. 2019 Jun 20;380(25):2395-2405
pubmed: 31157962
Med Image Comput Comput Assist Interv. 2013;16(Pt 3):396-403
pubmed: 24505786
Cytometry A. 2017 Jun;91(6):566-573
pubmed: 28192639
Ann Pathol. 1998 Nov;18(5):385-90
pubmed: 9864574
N Engl J Med. 2004 Dec 30;351(27):2817-26
pubmed: 15591335
J Clin Oncol. 2000 Jul;18(14):2695-701
pubmed: 10894868
Cancer Treat Res Commun. 2021;26:100306
pubmed: 33444922
Med Image Anal. 2016 Oct;33:170-175
pubmed: 27423409
Mod Pathol. 2008 Oct;21(10):1255-61
pubmed: 18360352
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Histopathology. 2002 Sep;41(3A):154-61
pubmed: 12405947
N Engl J Med. 2018 Jul 12;379(2):111-121
pubmed: 29860917
CA Cancer J Clin. 2019 Nov;69(6):438-451
pubmed: 31577379
Breast Cancer Res Treat. 2021 Jan;185(1):215-227
pubmed: 32939592
Annu Rev Biomed Eng. 2016 Jul 11;18:387-412
pubmed: 27420575
Mod Pathol. 2006 Feb;19(2):195-207
pubmed: 16341153
Tumour Biol. 2017 Mar;39(3):1010428317694550
pubmed: 28347240
Front Bioeng Biotechnol. 2019 Jun 21;7:145
pubmed: 31281813
BMC Cancer. 2018 May 30;18(1):610
pubmed: 29848291
JAMA Oncol. 2021 Mar 01;7(3):370-378
pubmed: 33475714
NPJ Breast Cancer. 2022 Oct 4;8(1):113
pubmed: 36192400
Ann Oncol. 2022 Jan;33(1):89-98
pubmed: 34756513
Int J Cancer. 2020 Feb 1;146(3):769-780
pubmed: 30977119
Breast Cancer Res Treat. 2004 Jun;85(3):219-22
pubmed: 15111759
Breast Cancer Res Treat. 1985;5(1):3-10
pubmed: 3978246
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S509-15
pubmed: 26001860
Biometrics. 1989 Mar;45(1):255-68
pubmed: 2720055
Sci Rep. 2016 Sep 07;6:32706
pubmed: 27599752
J Clin Oncol. 2008 Jul 1;26(19):3153-8
pubmed: 18490649

Auteurs

Yuli Chen (Y)

Shaanxi Normal University, School of Computer Science, Xi'an, China.
Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.

Haojia Li (H)

Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.

Andrew Janowczyk (A)

Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.
Precision Oncology Center, University of Lausanne, Lausanne, Switzerland.

Paula Toro (P)

Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.

Germán Corredor (G)

Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.
Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.

Jon Whitney (J)

Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.

Cheng Lu (C)

Shaanxi Normal University, School of Computer Science, Xi'an, China.
Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.

Can F Koyuncu (CF)

Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.

Mojgan Mokhtari (M)

Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.

Christina Buzzy (C)

Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.

Shridar Ganesan (S)

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Michael D Feldman (MD)

Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Pingfu Fu (P)

Department of Population and Quantitative Health Sciences, Case Western Reserve University, School of Medicine, Cleveland, OH, USA.

Haley Corbin (H)

University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Aparna Harbhajanka (A)

University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Hannah Gilmore (H)

University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Lori J Goldstein (LJ)

Fox Chase Cancer Center, Philadelphia, PA, USA.

Nancy E Davidson (NE)

Fred Hutchinson Cancer Research Center, University of Washington, and Seattle Cancer Care Alliance, Seattle, WA, USA.

Sangeeta Desai (S)

Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

Vani Parmar (V)

Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

Anant Madabhushi (A)

Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA. anantm@emory.edu.
Louis Stokes VA Medical Center, Cleveland, OH, USA. anantm@emory.edu.

Classifications MeSH